
  
    
      
        Introduction_NNP
        MI_NNP is_VBZ an_DT important_JJ end-point_JJ in_IN clinical_JJ trials_NNS ._. The_DT
        prevention_NN of_IN MI_NNP has_VBZ in_IN fact_NN been_VBN the_DT primary_JJ treatment_NN
        effect_NN assessed_VBN in_IN recent_JJ trials_NNS of_IN antiplatelet_NN and_CC
        antithrombin_NN therapies_NNS [_NN 1_CD ,_, 2_CD ,_, 3_CD ,_, 4_CD ,_, 5_CD ,_, 6_CD ,_, 7_CD ,_, 8_CD ,_, 9_CD ,_, 10_CD ,_,
        11_CD ]_NN ._. CECs_NNP are_VBP now_RB commonly_RB used_VBN to_TO adjudicate_NN suspected_VBD
        end-point_JJ events_NNS in_IN cardiovascular_JJ clinical_JJ trials_NNS ._. Limited_JJ
        information_NN has_VBZ ,_, however_RB ,_, been_VBN published_VBN about_IN the_DT
        classification_NN of_IN the_DT cause_NN of_IN death_NN [_NN 12_CD ,_, 13_CD ,_, 14_CD ,_, 15_CD ,_, 16_CD ]_NN
        or_CC the_DT adjudication_NN of_IN nonfatal_NN end-points_JJ [_NN 17_CD ,_, 18_CD ,_, 19_CD ,_,
        20_CD ,_, 21_CD ,_, 22_CD ,_, 23_CD ,_, 24_CD ]_NN in_IN these_DT trials_NNS ._. The_DT rates_NNS of_IN end-point_JJ
        events_NNS can_MD vary_VB considerably_RB depending_VBG on_IN whether_IN
        committees_NNS merely_RB confirm_VBP events_NNS reported_VBN by_IN investigators_NNS
        or_CC whether_IN they_PRP adjudicate_NN all_DT suspected_VBN events_NNS identified_VBN
        by_IN data_NNS screening_NN ._.
        In_IN the_DT PURSUIT_NNP trial_NN [_NN 6_CD ]_NN ,_, a_DT central_JJ ,_, independent_JJ CEC_NNP
        systematically_RB identified_VBD and_CC adjudicated_JJ all_DT suspected_VBN
        non-fatal_JJ MIs_NNP that_WDT occurred_VBD after_IN enrolment_NN and_CC through_IN a_DT
        30_CD -_: day_NN follow-up_JJ ._. The_DT rationale_NN for_IN CEC_NNP adjudication_NN was_VBD
        the_DT need_NN for_IN a_DT systematic_JJ ,_, unbiased_JJ ,_, independent_JJ ,_, and_CC
        standard_JJ assessment_NN of_IN this_DT end-point_JJ in_IN a_DT large_JJ ,_,
        international_JJ trial_NN ._. To_TO understand_VB the_DT role_NN of_IN such_JJ a_DT
        committee_NN ,_, and_CC to_TO provide_VB recommendations_NNS for_IN future_JJ
        efforts_NNS ,_, we_PRP reviewed_VBD the_DT results_NNS of_IN the_DT CEC_NNP process_NN used_VBN in_IN
        the_DT PURSUIT_NNP trial_NN to_TO identify_VB and_CC adjudicate_NN suspected_VBD
        end-point_JJ MIs_NNP ._.
      
      
        Methods_NNP
        
          The_DT PURSUIT_NNP trial_NN
          The_DT PURSUIT_NNP trial_NN [_NN 6_CD ]_NN enrolled_VBD 10_CD ,_, 948_CD patients_NNS at_IN 726_CD
          hospitals_NNS in_IN 27_CD countries_NNS from_IN North_NNP America_NNP ,_, Latin_NNP
          America_NNP ,_, Western_NNP Europe_NNP ,_, and_CC Eastern_NNP Europe_NNP ._. Patients_NNS
          with_IN acute_JJ coronary_JJ syndromes_NNS without_IN persistent_JJ
          ST-segment_NNP elevation_NN were_VBD randomly_RB assigned_VBN to_TO placebo_NN or_CC
          eptifibatide_NN ._. The_DT inclusion_NN and_CC exclusion_NN criteria_NNS ,_, as_RB
          well_RB as_IN treatment_NN regimens_NNS ,_, have_VBP been_VBN published_VBN elsewhere_RB
          [_NN 6_CD ]_NN ._. The_DT primary_JJ end-point_JJ was_VBD a_DT composite_NN of_IN death_NN or_CC
          non-fatal_JJ MI_NNP (_( or_CC reinfarction_NN in_IN patients_NNS with_IN MI_NNP at_IN
          enrolment_NN )_) by_IN 30_CD -_: day_NN follow-up_JJ as_IN adjudicated_JJ by_IN the_DT CEC_NNP ._.
          The_DT composite_JJ end-point_JJ was_VBD also_RB calculated_VBN using_VBG the_DT
          site_NN investigator_NN determination_NN of_IN MI_NNP from_IN case_NN report_NN
          forms_NNS ._. We_PRP assessed_VBD the_DT incidence_NN of_IN end-point_JJ
          (_( post-enrolment_JJ )_) MI_NNP among_IN all_DT 10_CD ,_, 948_CD patients_NNS enrolled_VBD in_IN
          the_DT PURSUIT_NNP trial_NN ._.
        
        
          End-point_NNP definitions_NNS
          The_DT definition_NN of_IN end-point_JJ MI_NNP included_VBD a_DT first_JJ MI_NNP
          (_( for_IN patients_NNS without_IN MI_NNP at_IN enrolment_NN )_) or_CC reinfarction_NN
          (_( for_IN patients_NNS who_WP had_VBD a_DT MI_NNP at_IN enrolment_NN )_) ,_, according_VBG to_TO
          clinical_JJ ,_, electrocardiography_NN (_( ECG_NNP )_) ,_, and_CC laboratory_NN
          criteria_NNS (_( see_VB Appendix_NNP )_) ._. A_DT MI_NNP present_JJ at_IN enrolment_NN was_VBD
          not_RB considered_VBN an_DT end-point_JJ MI_NNP and_CC was_VBD not_RB adjudicated_JJ by_IN
          the_DT CEC_NNP ._.
        
        
          Data_NNP collection_NN
          Data_NNP were_VBD collected_VBN using_VBG standard_JJ case_NN report_NN forms_NNS ._.
          Additional_JJ information_NN collected_VBN from_IN all_DT patients_NNS
          included_VBD cardiac_JJ enzymes_NNS ,_, ECGs_NNP (_( performed_VBN at_IN the_DT time_NN of_IN
          the_DT qualifying_VBG episode_NN ,_, at_IN enrolment_NN ,_, at_IN 24_CD hours_NNS ,_, at_IN
          first_JJ hospital_NN discharge_NN ,_, and_CC at_IN 30_CD -_: day_NN follow-up_JJ )_) ,_,
          revascularisation_NN procedure_NN reports_NNS ,_, details_NNS of_IN ischemic_JJ
          episodes_NNS ,_, clinical_JJ complications_NNS ,_, medications_NNS ,_, and_CC
          readmission_NN records_NNS ._. All_DT enzyme_NN values_NNS for_IN each_DT patient_NN
          were_VBD reported_VBN ;_: study_NN monitors_VBZ then_RB verified_VBN them_PRP against_IN
          source_NN documents_NNS ._. Site_NNP investigators_NNS were_VBD asked_VBN to_TO submit_VB
          supporting_VBG documents_NNS for_IN patients_NNS with_IN suspected_VBN MI_NNP ,_,
          which_WDT included_VBD discharge_NN summaries_NNS and_CC additional_JJ ECGs_NNP
          during_IN the_DT suspected_VBN event_NN ._. Progress_NN notes_NNS and_CC procedure_NN
          notes_NNS were_VBD also_RB collected_VBN if_IN necessary_JJ ._. An_DT independent_JJ ,_,
          blinded_JJ core_NN laboratory_NN read_VBP the_DT specified_VBN ECGs_NNP and_CC
          identified_VBN suspected_VBN MIs_NNP ,_, defined_VBN as_IN new_JJ Q_NNP waves_NNS ≥_NN 0_CD ._. 04_CD s_VBZ
          in_IN two_CD contiguous_JJ leads_NNS ._. Overall_RB ,_, data_NNS for_IN creatine_NN
          kinase-myocardial_JJ band_NN (_( CK-MB_NNP )_) were_VBD missing_VBG for_IN only_RB 26_CD
          patients_NNS (_( 0_CD ._. 2_LS %_NN )_) ,_, data_NNS for_IN baseline_NN ECG_NNP were_VBD missing_VBG for_IN
          44_CD patients_NNS (_( 0_CD ._. 4_LS %_NN )_) ,_, and_CC data_NNS for_IN later_RB ECGs_NNP were_VBD missing_VBG
          for_IN 36_CD patients_NNS (_( 0_CD ._. 3_LS %_NN )_) ._.
        
        
          Process_NNP for_IN event_NN adjudication_NN
          The_DT CEC_NNP was_VBD a_DT group_NN dedicated_VBN to_TO event_NN adjudication_NN
          within_IN the_DT North_JJ American_NNP Trial_NNP Co-ordinating_NNP Centre_NNP at_IN
          the_DT Duke_NNP Clinical_NNP Research_NNP Institute_NNP ._. The_DT group_NN consisted_VBD
          of_IN a_DT managing_VBG supervisor_NN ,_, clinical_JJ coordinators_NNS with_IN a_DT
          nursing_NN or_CC clinical_JJ research_NN background_NN ,_, administrative_JJ
          assistants_NNS ,_, cardiology_NN fellows_NNS ,_, and_CC cardiology_NN faculty_NN
          members_NNS ._. The_DT CEC_NNP helped_VBD define_VB clinical_JJ end-point_JJ events_NNS ,_,
          helped_VBD develop_VB computer_NN algorithms_NNS to_TO identify_VB patients_NNS
          with_IN suspected_VBN end-point_JJ events_NNS from_IN data_NNS from_IN case_NN
          report_NN forms_NNS ,_, worked_VBD with_IN monitoring_VBG groups_NNS to_TO collect_VB
          supplemental_JJ medical_JJ records_NNS for_IN event_NN review_NN ,_, and_CC
          adjudicated_JJ suspected_VBN clinical_JJ end-point_JJ events_NNS ._.
          A_DT schematic_JJ diagram_NN of_IN the_DT clinical_JJ event_NN adjudication_NN
          process_NN is_VBZ shown_VBN in_IN Figure_NN 1_CD ._. Computer_NNP algorithms_NNS
          systematically_RB identified_VBN key_JJ variables_NNS from_IN the_DT database_NN
          that_WDT could_MD indicate_VB the_DT occurrence_NN of_IN a_DT post-enrolment_JJ
          (_( end-point_JJ )_) MI_NNP ._. These_DT variables_NNS ,_, which_WDT were_VBD determined_VBN
          from_IN clinical_JJ expertise_NN and_CC trial_NN experience_NN ,_, included_VBD
          elevated_VBD cardiac_JJ enzymes_NNS ,_, ECG_NNP core_NN laboratory_NN
          identification_NN of_IN suspected_VBN MI_NNP ,_, recurrent_JJ ischemic_JJ
          events_NNS ,_, urgent_JJ revascularisations_NNS ,_, or_CC site_NN investigator_NN
          assessment_NN of_IN a_DT post-enrolment_JJ MI_NNP ._. The_DT system_NN was_VBD
          designed_VBN for_IN broad_JJ identification_NN of_IN all_DT patients_NNS with_IN
          possible_JJ MI_NNP after_IN enrolment_NN ._. A_DT report_NN of_IN all_DT patients_NNS
          with_IN suspected_VBN end-point_JJ MI_NNP was_VBD generated_VBN according_VBG to_TO
          '_POS hits_NNS '_POS on_IN the_DT variables_NNS already_RB listed_VBN ._.
          Each_DT patient_NN with_IN a_DT suspected_VBN MI_NNP had_VBD a_DT clinical_JJ folder_NN
          prepared_VBN by_IN CEC_NNP staff_NN at_IN the_DT Duke_NNP Clinical_NNP Research_NNP
          Institute_NNP ._. Folders_NNP included_VBD the_DT case_NN report_NN form_NN and_CC
          ancillary_JJ data_NNS forms_NNS ,_, discharge_NN summaries_NNS ,_, cardiac_JJ enzyme_NN
          results_NNS ,_, ECGs_NNP ,_, and_CC a_DT data_NNS worksheet_NN that_IN summarised_JJ
          clinical_JJ events_NNS ,_, procedures_NNS ,_, and_CC cardiac_JJ enzyme_NN
          information_NN ._. Medical_JJ records_NNS were_VBD translated_VBN into_IN English_NNP
          if_IN necessary_JJ ,_, using_VBG physicians_NNS literate_NN in_IN the_DT other_JJ
          language_NN when_WRB possible_JJ ._.
          Each_DT case_NN was_VBD reviewed_VBN independently_RB by_IN two_CD physicians_NNS
          blinded_JJ to_TO treatment_NN in_IN the_DT phase_NN I_PRP review_VBP ._. The_DT case_NN was_VBD
          classified_VBN as_IN resolved_VBN if_IN the_DT physicians_NNS agreed_VBD that_IN a_DT MI_NNP
          had_VBD or_CC had_VBN not_RB occurred_VBN ._. Cases_NNS in_IN which_WDT there_EX was_VBD
          disagreement_NN between_IN the_DT two_CD CEC_NNP physicians_NNS were_VBD
          forwarded_JJ to_TO a_DT second-level_JJ (_( phase_NN II_NNP )_) review_NN for_IN
          adjudication_NN by_IN consensus_NN of_IN a_DT committee_NN of_IN faculty_NN
          cardiologists_NNS (_( Fig_NNP ._. 1_LS )_) ._. The_DT committee_NN members_NNS were_VBD also_RB
          blinded_JJ to_TO treatment_NN and_CC to_TO the_DT result_NN of_IN the_DT phase_NN I_PRP
          review_VBP ._. Physicians_NNPS could_MD request_VB additional_JJ medical_JJ
          records_NNS ,_, if_IN necessary_JJ ,_, to_TO adjudicate_NN a_DT suspected_VBN event_NN ._.
          If_IN additional_JJ records_NNS were_VBD obtained_VBN ,_, the_DT case_NN was_VBD
          re-reviewed_JJ to_TO ensure_VB that_IN decisions_NNS were_VBD based_VBN on_IN
          similar_JJ documents_NNS ._. For_IN quality_NN assurance_NN ,_, 10_CD %_NN of_IN the_DT
          cases_NNS with_IN agreement_NN by_IN the_DT phase_NN I_PRP physicians_NNS were_VBD
          reviewed_VBN in_IN a_DT blinded_JJ fashion_NN by_IN the_DT phase_NN II_NNP committee_NN
          to_TO determine_VB whether_IN there_EX were_VBD any_DT systematic_JJ
          inconsistencies_NNS with_IN the_DT phase_NN I_PRP reviews_VBZ ._. There_EX were_VBD no_DT
          inconsistencies_NNS found_VBD ._.
        
        
          Statistical_NNP analysis_NN
          Variables_NNP were_VBD summarised_JJ as_IN percentages_NNS for_IN
          dichotomous_JJ variables_NNS or_CC medians_NNS (_( 25_CD th_NN and_CC 75_CD th_NN
          percentiles_NNS )_) for_IN continuous_JJ variables_NNS ._. The_DT Χ_NN 2_CD test_NN was_VBD
          used_VBN to_TO calculate_VB 
          P_NN values_NNS ._.
        
      
      
        Results_NNS
        Overall_RB ,_, 5005_CD patients_NNS with_IN suspected_VBN MI_NNP after_IN enrolment_NN
        (_( 46_CD %_NN )_) were_VBD identified_VBN and_CC adjudicated_JJ by_IN the_DT CEC_NNP ._. Table_NNP
        1_CD presents_VBZ the_DT number_NN of_IN patients_NNS enrolled_VBD and_CC the_DT number_NN of_IN
        patients_NNS with_IN an_DT end-point_JJ MI_NNP identified_VBN by_IN the_DT CEC_NNP or_CC the_DT
        site_NN ,_, both_DT or_CC neither_DT ,_, by_IN geographic_JJ region_NN ._. The_DT proportion_NN
        of_IN patients_NNS with_IN MI_NNP adjudicated_JJ by_IN the_DT CEC_NNP was_VBD similar_JJ in_IN
        North_NNP America_NNP ,_, Latin_NNP America_NNP and_CC Western_NNP Europe_NNP ,_, but_CC tended_VBD
        to_TO be_VB higher_JJR in_IN Eastern_NNP Europe_NNP ._.
        As_IN expected_VBN ,_, because_IN of_IN the_DT rigorous_JJ effort_NN by_IN the_DT CEC_NNP
        to_TO identify_VB all_DT suspected_VBN MIs_NNP for_IN adjudication_NN ,_, the_DT process_NN
        identified_VBN more_RBR end-point_JJ events_NNS than_IN did_VBD the_DT site_NN
        investigators_NNS (_( Table_NNP 2_LS )_) ._. Eptifibatide_NNP reduced_VBD the_DT incidence_NN
        of_IN death_NN or_CC MI_NNP in_IN the_DT PURSUIT_NNP trial_NN by_IN 1_CD ._. 5_CD %_NN (_( 15_CD ._. 7_CD %_NN versus_CC
        14_CD ._. 2_LS %_NN ;_: 
        P_NN =_SYM 0_CD ._. 042_CD )_) at_IN 30_CD days_NNS [_NN 6_CD ]_NN ._. This_DT
        benefit_NN was_VBD driven_VBN primarily_RB by_IN a_DT reduction_NN in_IN nonfatal_NN MI_NNP ._.
        We_PRP noted_VBD smaller_JJR absolute_JJ and_CC relative_JJ treatment_NN effects_NNS
        when_WRB the_DT CEC-determined_NNP MI_NNP rates_NNS were_VBD used_VBN compared_VBN with_IN
        the_DT site_NN investigator-determined_JJ rates_NNS ._.
        The_DT proportion_NN of_IN patients_NNS enrolled_VBD who_WP had_VBD a_DT suspected_VBN
        end-point_JJ MI_NNP ranged_VBD from_IN 41_CD %_NN in_IN North_NNP America_NNP to_TO 50_CD %_NN in_IN
        Western_NNP Europe_NNP (_( Table_NNP 3_LS )_) ._. Disagreements_NNP between_IN the_DT site_NN
        investigator_NN and_CC CEC_NNP assessment_NN of_IN MI_NNP occurred_VBD in_IN 9_CD %_NN of_IN all_DT
        patients_NNS enrolled_VBD in_IN the_DT trial_NN ,_, or_CC 983_CD of_IN the_DT 5005_CD patients_NNS
        with_IN suspected_VBN MI_NNP adjudicated_JJ by_IN the_DT CEC_NNP (_( 20_CD %_NN ;_: Table_NNP 3_LS )_) ._. Of_IN
        these_DT 983_CD patients_NNS with_IN disagreements_NNS ,_, 816_CD patients_NNS had_VBD a_DT
        MI_NNP assessed_VBN by_IN the_DT CEC_NNP but_CC not_RB by_IN the_DT site_NN investigator_NN ,_,
        and_CC 167_CD patients_NNS had_VBD a_DT MI_NNP identified_VBN by_IN site_NN investigators_NNS
        but_CC not_RB by_IN the_DT CEC_NNP ._.
      
      
        Discussion_NNP
        The_DT review_NN of_IN the_DT clinical-events_JJ classification_NN process_NN
        in_IN the_DT current_JJ study_NN raises_VBZ some_DT important_JJ issues_NNS for_IN
        clinical_JJ investigators_NNS ._. First_LS ,_, the_DT rates_NNS of_IN end-point_JJ
        infarction_NN or_CC re-infarction_JJ were_VBD higher_JJR than_IN those_DT reported_VBN
        in_IN prior_JJ trials_NNS of_IN patients_NNS with_IN acute_JJ coronary_JJ syndromes_NNS ._.
        Second_JJ ,_, the_DT CEC_NNP identified_VBD more_JJR events_NNS than_IN the_DT site_NN
        investigators_NNS ._. Third_NNP ,_, the_DT site_NN investigator_NN and_CC the_DT CEC_NNP
        assessments_NNS of_IN MI_NNP disagreed_VBD for_IN 20_CD %_NN of_IN the_DT patients_NNS
        reviewed_VBN by_IN the_DT CEC_NNP ._.
        CECs_NNP have_VBP become_VBN an_DT integral_JJ aspect_NN of_IN clinical_JJ trials_NNS
        of_IN new_JJ therapies_NNS for_IN patients_NNS with_IN acute_JJ coronary_JJ
        syndromes_NNS ._. The_DT primary_JJ function_NN of_IN these_DT committees_NNS has_VBZ
        been_VBN to_TO systematically_RB adjudicate_NN nonfatal_NN end-points_JJ such_JJ
        as_IN MI_NNP ._. The_DT first_JJ large_JJ trials_NNS in_IN these_DT patients_NNS used_VBD
        mortality_NN as_IN the_DT primary_JJ end-point_JJ ;_: thus_RB ,_, standardised_JJ
        assessment_NN of_IN patient_NN outcome_NN was_VBD not_RB required_VBN [_NN 25_CD ,_, 26_CD ,_,
        27_CD ]_NN ._. More_RBR recent_JJ trials_NNS ,_, however_RB ,_, have_VBP included_VBN nonfatal_NN
        end-points_JJ such_JJ as_IN MI_NNP ,_, congestive_JJ heart_NN failure_NN ,_, stroke_NN ,_, or_CC
        safety_NN measures_NNS as_IN part_NN of_IN composite_JJ clinical_JJ end-points_JJ ._.
        Myocardial_NNP infarction_NN has_VBZ been_VBN considered_VBN a_NNP '_POS hard_JJ '_POS
        end-point_JJ ,_, but_CC its_PRP$ assessment_NN can_MD be_VB as_IN difficult_JJ in_IN
        clinical_JJ trials_NNS as_IN it_PRP is_VBZ in_IN clinical_JJ practice_NN ,_, because_IN
        clinical_JJ ,_, laboratory_NN ,_, and_CC ECG_NNP data_NNS may_MD conflict_NN and_CC
        physicians_NNS often_RB disagree_VBP whether_IN a_DT patient_NN has_VBZ suffered_VBN a_DT
        MI_NNP ._. An_DT example_NN of_IN this_DT difficulty_NN is_VBZ the_DT evaluation_NN of_IN
        small_JJ enzyme_NN elevations_NNS in_IN patients_NNS undergoing_VBG percutaneous_JJ
        coronary_JJ intervention_NN [_NN 28_CD ]_NN ._. Although_IN these_DT low-level_JJ
        enzyme_NN elevations_NNS are_VBP defined_VBN as_IN MIs_NNP in_IN many_JJ trial_NN
        protocols_NNS ,_, physicians_NNS do_VBP not_RB consistently_RB consider_VB them_PRP to_TO
        be_VB infarctions_NNS in_IN daily_JJ clinical_JJ practice_NN and_CC therefore_RB may_MD
        be_VB reluctant_JJ to_TO report_VB them_PRP as_IN such_JJ ._.
        The_DT rates_NNS of_IN infarction_NN as_IN adjudicated_JJ by_IN the_DT CEC_NNP in_IN the_DT
        PURSUIT_NNP trial_NN were_VBD higher_RBR than_IN reported_VBD in_IN previous_JJ trials_NNS
        of_IN patients_NNS with_IN acute_JJ coronary_JJ syndromes_NNS ,_, for_IN several_JJ
        reasons_NNS [_NN 1_CD ,_, 7_CD ,_, 8_CD ,_, 29_CD ]_NN ._. First_LS ,_, the_DT PURSUIT_NNP trial_NN CEC_NNP effort_NN
        was_VBD more_RBR liberal_JJ in_IN its_PRP$ identification_NN of_IN possible_JJ events_NNS ._.
        Committee_NN physicians_NNS reviewed_VBD events_NNS for_IN almost_RB 50_CD %_NN of_IN the_DT
        patients_NNS in_IN the_DT trial_NN ,_, which_WDT is_VBZ nearly_RB double_VB the_DT
        percentage_NN that_WDT underwent_VBD adjudication_NN by_IN the_DT same_JJ CEC_NNP
        group_NN in_IN two_CD other_JJ trials_NNS :_: Integrilin_NNP to_TO Minimize_NNP Platelet_NNP
        Aggregation_NNP and_CC Coronary_NNP Thrombosis_NNP (_( IMPACT-II_NNP )_) [_NN 9_CD ]_NN ,_, and_CC
        Global_NNP Use_NN of_IN Strategies_NNS to_TO Open_NNP Occluded_NNP Arteries_NN in_IN Acute_NNP
        Coronary_NNP Syndromes_NNP (_( GUSTO-IIb_NNP )_) [_NN 1_CD ]_NN ._. Second_JJ ,_, the_DT definition_NN
        of_IN MI_NNP is_VBZ evolving_VBG and_CC has_VBZ varied_VBN among_IN clinical_JJ trials_NNS in_IN
        this_DT patient_NN population_NN ._. For_IN example_NN ,_, criteria_NNS for_IN MI_NNP after_IN
        bypass_NN surgery_NN in_IN the_DT GUSTO-IIb_NNP trial_NN were_VBD more_RBR stringent_JJ
        than_IN those_DT in_IN the_DT PURSUIT_NNP trial_NN ,_, requiring_VBG two_CD of_IN three_CD
        criteria_NNS to_TO be_VB met_VBN (_( CK_NNP or_CC CK-MB_NNP fraction_NN ≥_NN 5_CD times_NNS the_DT
        upper_JJ limit_NN of_IN normal_JJ ,_, two_CD new_JJ Q_NNP waves_NNS ,_, or_CC new_JJ regional_JJ
        wall-motion_JJ abnormalities_NNS )_) ._. Finally_RB ,_, more_RBR cardiac_JJ enzyme_NN
        samples_NNS were_VBD collected_VBN per_IN patient_NN in_IN the_DT PURSUIT_NNP trial_NN
        than_IN in_IN GUSTO-IIb_NNP (_( median_JJ [_NN 25_CD th_NN ,_, 75_CD th_NN ]_NN 4_CD ._. 5_CD [_NN 3_CD ,_, 7_CD ]_NN versus_CC
        3_CD [_NN 1_CD ,_, 4_CD ]_NN )_) (_( RAHarrington_NNP ,_, unpublished_JJ data_NNS )_) ._. These_DT factors_NNS ,_,
        particularly_RB the_DT systematic_JJ collection_NN of_IN cardiac_JJ enzymes_NNS
        (_( missing_VBG for_IN only_RB 0_CD ._. 2_CD %_NN of_IN the_DT patients_NNS )_) ,_, contributed_VBD to_TO a_DT
        higher_JJR ascertainment_NN of_IN MI_NNP in_IN the_DT PURSUIT_NNP trial_NN ._. Trials_NNP
        that_WDT rely_VBP on_IN investigator-reported_JJ MI_NNP probably_RB
        underestimate_NN the_DT true_JJ event_NN rate_NN ._.
        Before_IN implementation_NN of_IN the_DT CEC_NNP process_NN ,_, the_DT
        International_NNP Steering_NNP Committee_NNP agreed_VBD on_IN the_DT definitions_NNS
        for_IN MI_NNP ,_, which_WDT were_VBD based_VBN on_IN experience_NN and_CC clinical_JJ
        expertise_NN ._. Because_IN of_IN the_DT global_JJ nature_NN of_IN the_DT PURSUIT_NNP
        investigation_NN ,_, attempts_NNS were_VBD made_VBN to_TO model_VB definitions_NNS
        after_IN everyday_JJ clinical_JJ practice_NN ._. The_DT study_NN protocol_NN
        provided_VBD the_DT end-point_JJ definitions_NNS ,_, so_IN that_IN the_DT CEC_NNP and_CC
        site_NN investigators_NNS had_VBD the_DT same_JJ set_NN of_IN criteria_NNS to_TO classify_VB
        MI_NNP ._. Nevertheless_RB ,_, the_DT site_NN investigators_NNS underreported_JJ
        infarctions_NNS ._. Similar_JJ findings_NNS have_VBP been_VBN noted_VBN in_IN prior_JJ
        trials_NNS [_NN 1_CD ,_, 9_CD ,_, 22_CD ,_, 23_CD ,_, 30_CD ,_, 31_CD ]_NN ._.
        The_DT strategy_NN used_VBN to_TO identify_VB suspected_VBN infarctions_NNS can_MD
        affect_VB the_DT proportion_NN of_IN events_NNS with_IN disagreements_NNS ._. Some_DT
        trials_NNS have_VBP confirmed_VBN events_NNS reported_VBD only_RB by_IN the_DT
        investigators_NNS [_NN 5_CD ,_, 7_CD ,_, 8_CD ,_, 11_CD ,_, 29_CD ,_, 30_CD ]_NN ,_, whereas_IN other_JJ trials_NNS
        have_VBP adjudicated_JJ all_DT suspected_VBN events_NNS identified_VBN by_IN
        systematic_JJ screening_NN of_IN patient_NN data_NNS [_NN 1_CD ,_, 2_CD ,_, 3_CD ,_, 9_CD ,_, 31_CD ,_, 32_CD ]_NN ._.
        In_IN the_DT first_JJ strategy_NN ,_, the_DT CEC_NNP event_NN rates_NNS will_MD be_VB the_DT same_JJ
        as_IN or_CC lower_JJR than_IN the_DT site_NN investigator-reported_JJ rates_NNS ._. In_IN
        the_DT second_NN ,_, the_DT CEC_NNP event_NN rates_NNS may_MD be_VB higher_JJR ,_, lower_RBR ,_, or_CC
        the_DT same_JJ as_IN the_DT site_NN investigator-reported_JJ rates_NNS ._.
        The_DT impact_NN of_IN adjudication_NN of_IN cases_NNS from_IN other_JJ regions_NNS
        of_IN the_DT world_NN by_IN physicians_NNS based_VBN in_IN North_NNP America_NNP is_VBZ
        unknown_JJ ._. In_IN the_DT current_JJ study_NN ,_, however_RB ,_, medical_JJ records_NNS
        were_VBD translated_VBN to_TO English_NNP ,_, physicians_NNS fluent_JJ in_IN other_JJ
        languages_NNS were_VBD used_VBN when_WRB needed_VBN ,_, and_CC the_DT criteria_NNS for_IN
        re-infarction_JJ were_VBD based_VBN ,_, for_IN the_DT most_JJS part_NN ,_, on_IN objective_NN
        data_NNS such_JJ as_IN enzyme_NN and_CC ECG_NNP data_NNS ._.
        There_EX are_VBP several_JJ key_JJ implications_NNS of_IN these_DT findings_NNS ._.
        The_DT strategy_NN used_VBN to_TO identify_VB and_CC adjudicate_NN end-point_JJ
        events_NNS is_VBZ one_CD of_IN many_JJ factors_NNS to_TO be_VB considered_VBN when_WRB

        comparing_VBG event_NN rates_NNS between_IN clinical_JJ studies_NNS ._. During_IN
        trial_NN planning_NN ,_, the_DT events_NNS classification_NN strategy_NN being_VBG
        considered_VBN may_MD also_RB have_VB an_DT important_JJ impact_NN on_IN estimation_NN
        of_IN event_NN rates_NNS and_CC the_DT calculations_NNS of_IN sample_NN size_NN and_CC
        power_NN ._. Education_NNP and_CC training_NN of_IN clinical_JJ investigators_NNS
        regarding_VBG end-point_JJ definitions_NNS and_CC ascertainment_NN may_MD help_VB
        in_IN minimising_VBG differences_NNS between_IN CEC_NNP and_CC site_NN investigator_NN
        assessments_NNS of_IN end-points_JJ ._. Finally_RB ,_, the_DT strategy_NN and_CC rigor_NN
        of_IN the_DT clinical_JJ event_NN adjudication_NN process_NN used_VBN may_MD
        influence_VB the_DT interpretation_NN of_IN trial_NN results_NNS by_IN the_DT
        clinical_JJ and_CC regulatory_JJ communities_NNS ._. We_PRP believe_VBP that_IN CEC_NNP
        adjudication_NN of_IN suspected_VBN nonfatal_NN MI_NNP end-point_JJ events_NNS is_VBZ
        important_JJ to_TO provide_VB independent_JJ ,_, unbiased_JJ ,_, standard_JJ ,_,
        systematic_JJ assessments_NNS ,_, particularly_RB in_IN trials_NNS that_WDT include_VBP
        broad_JJ geographic_JJ regions_NNS and_CC different_JJ clinical_JJ practice_NN
        settings_NNS ._.
      
      
        Conclusion_NNP
        Nonfatal_NNP MI_NNP ,_, inherently_RB undesirable_JJ ,_, is_VBZ an_DT important_JJ
        clinical_JJ event_NN and_CC an_DT important_JJ component_NN of_IN clinical_JJ trial_NN
        end-points_JJ ._. CEC_NNP adjudication_NN of_IN infarction_NN is_VBZ necessary_JJ to_TO
        provide_VB standardised_JJ ,_, systematic_JJ ,_, independent_JJ ,_, and_CC unbiased_JJ
        assessments_NNS of_IN end-points_JJ in_IN clinical_JJ investigation_NN ._. In_IN the_DT
        PURSUIT_NNP trial_NN ,_, the_DT assessment_NN of_IN infarction_NN by_IN site_NN
        investigators_NNS versus_CC that_IN of_IN a_DT central_JJ CEC_NNP disagreed_VBD :_: more_JJR
        infarctions_NNS were_VBD identified_VBN by_IN the_DT CEC_NNP than_IN by_IN the_DT site_NN
        investigators_NNS ._. The_DT impact_NN of_IN these_DT findings_NNS affects_VBZ the_DT
        comparison_NN of_IN event_NN rates_NNS between_IN trials_NNS as_RB well_RB as_IN the_DT
        design_NN of_IN future_JJ trials_NNS ._.
      
      
        Competing_VBG interests_NNS
        None_NN declared_VBD ._.
      
      
        Abbreviations_NNP
        CEC_NNP =_SYM clinical_JJ events_NNS committee_NN ;_: CK-MB_NNP =_SYM creatine_NN
        kinase-myocardial_JJ band_NN ;_: ECG_NNP =_SYM electrocardiography_NN ;_: MI_NNP =_SYM
        myocardial_NN infarction_NN ;_: PURSUIT_NNP =_SYM Platelet_NNP Glycoprotein_NNP
        IIb_NNP /_NN IIIa_NNP in_IN Unstable_NNP Angina_NNP :_: Receptor_NNP Suppression_NN Using_VBG
        Integrilin_NNP (_( Eptifibatide_NNP )_) Therapy_NNP ._.
      
      
        Appendix_NNP :_: definition_NN for_IN end-point_JJ (_( post-enrolment_JJ )_)
        myocardial_NN infarction_NN
        
          Enzyme_NNP criteria_NNS
          1_LS ._. Myocardial_NNP infarction_NN (_( MI_NNP )_) events_NNS without_IN
          documentation_NN of_IN a_DT prior_RB MI_NNP during_IN the_DT admission_NN :_:
          creatine_NN kinase-myocardial_JJ band_NN (_( CK-MB_NNP )_) elevated_VBD above_IN
          the_DT upper_JJ limit_NN of_IN normal_JJ (_( ULN_NNP )_) and_CC ≥_NN 3_CD %_NN of_IN total_JJ CK_NNP ._. If_IN
          CK-MB_NNP is_VBZ unavailable_JJ ,_, then_RB total_JJ CK_NNP >_NN 2_CD ×_NN ULN_NNP ._.
          2_LS ._. MI_NNP events_NNS with_IN documentation_NN of_IN a_DT prior_JJ infarction_NN
          during_IN the_DT admission_NN ,_, either_CC before_IN or_CC at_IN enrolment_NN :_:
          If_IN <_NN 18_CD hours_NNS since_IN previous_JJ MI_NNP ._. Recurrent_NNP ,_, severe_JJ
          ischemic_JJ discomfort_NN and_CC new_JJ or_CC recurrent_JJ ST-segment_NNP
          elevation_NN ≥_NN 0_CD ._. 1_CD mV_NN in_IN at_IN least_JJS two_CD contiguous_JJ leads_NNS ,_,
          either_CC persisting_VBG for_IN ≥_NN 30_CD min_NN ._.
          If_IN ≥_NN 18_CD hours_NNS since_IN previous_JJ MI_NNP ._. Re-elevation_NNP of_IN CK-MB_NNP
          to_TO above_IN the_DT ULN_NNP (_( if_IN prior_JJ CK-MB_NNP was_VBD within_IN normal_JJ range_NN )_)
          or_CC >_NN 50_CD %_NN above_IN the_DT prior_JJ level_NN (_( if_IN prior_JJ CK-MB_NNP was_VBD
          above_IN the_DT ULN_NNP )_) ._. If_IN CK-MB_NNP is_VBZ unavailable_JJ :_: either_CC total_JJ CK_NNP
          ≥_NN 2_CD ×_NN ULN_NNP and_CC increased_VBN by_IN ≥_NN 25_CD %_NN ;_: or_CC ≥_NN 1_CD ._. 5_CD ×_NN ULN_NNP and_CC
          increased_VBN by_IN ≥_NN 200_CD IU_NNP above_IN the_DT previous_JJ value_NN ._.
          3_LS ._. Periprocedural_NNP MI_NNP events_NNS (_( occurring_VBG during_IN or_CC
          <_NN 24_CD hours_NNS after_IN percutaneous_JJ coronary_JJ intervention_NN )_) :_:
          CK-MB_NNP ≥_NN 3_CD ×_NN ULN_NNP and_CC >_NN 50_CD %_NN above_IN the_DT prior_JJ nadir_NN value_NN ._.
          If_IN CK-MB_NNP is_VBZ unavailable_JJ ,_, then_RB total_JJ CK_NNP ≥_NN 3_CD ×_NN ULN_NNP ._.
          4_LS ._. Perioperative_NNP MI_NNP events_NNS occurring_VBG during_IN or_CC <_NN 36_CD
          hours_NNS after_IN bypass_NN surgery_NN )_) :_: CK-MB_NNP ≥_NN 5_CD ×_NN ULN_NNP (_( or_CC CK_NNP ,_, in_IN
          the_DT absence_NN of_IN CK-MB_NNP )_) ._.
        
        
          ECG_NNP criteria_NNS
          New_NNP ,_, significant_JJ Q_NNP waves_NNS or_CC Q-_NNP wave_NN equivalents_NNS ≥_NN 0_CD ._. 04_CD
          s_VBZ in_IN at_IN least_JJS two_CD contiguous_JJ leads_NNS ._. If_IN enzyme_NN or_CC ECG_NNP data_NNS
          are_VBP unavailable_JJ ,_, a_DT MI_NNP is_VBZ considered_VBN to_TO have_VB occurred_VBN when_WRB
          there_EX is_VBZ a_DT preponderance_NN of_IN clinical_JJ evidence_NN based_VBN on_IN
          patient_NN signs_NNS ,_, symptoms_NNS ,_, ECG_NNP changes_NNS ,_, and_CC pathological_JJ
          findings_NNS ._. When_WRB enzyme_NN or_CC ECG_NNP criteria_NNS are_VBP available_JJ ,_, they_PRP
          take_VBP precedence_NN ._.
        
      
    
  
